We’re Hiring
We’re Hiring

Press Release

Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ® Read more
lab testing

Advancing Vaccines
For Better Lives

Welcome to Valneva

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Our focused pipeline includes the world’s first vaccine against the chikungunya virus, the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Learn More

Check out our 2022 Annual Business Report

Learn More

Latest News

Follow Us

valnevase Valneva @valnevase ·
4 Dec

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
https://ow.ly/ltjI50QfgYT

Reply on Twitter 1731786353405276430 Retweet on Twitter 1731786353405276430 13 Like on Twitter 1731786353405276430 44 Twitter 1731786353405276430
valnevase Valneva @valnevase ·
4 Dec

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
https://ow.ly/P20550QeSA8

Reply on Twitter 1731554455722623179 Retweet on Twitter 1731554455722623179 13 Like on Twitter 1731554455722623179 41 Twitter 1731554455722623179
valnevase Valneva @valnevase ·
27 Nov

🎉🏆Congratulations are in order for our Valneva Scotland colleagues, who picked up the Innovation & Resilience award at Friday’s West Lothian Chamber of Commerce Business Excellence Ceremony! #LifeAtValneva #Innovation #Resilience

3

Reply on Twitter 1729179533184806984 Retweet on Twitter 1729179533184806984 6 Like on Twitter 1729179533184806984 28 Twitter 1729179533184806984
Load More